Huntington Steele LLC held its position in Johnson & Johnson (NYSE:JNJ) during the first quarter, Holdings Channel reports. The institutional investor owned 3,878 shares of the company’s stock at the end of the first quarter. Huntington Steele LLC’s holdings in Johnson & Johnson were worth $483,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in the stock. Lenox Wealth Advisors Inc. boosted its position in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares during the period. Thomas J. Herzfeld Advisors Inc. acquired a new position in Johnson & Johnson during the fourth quarter valued at $117,000. Empirical Finance LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at $144,000. Foundation Resource Management Inc. acquired a new position in Johnson & Johnson during the first quarter valued at $204,000. Finally, New Capital Management LP acquired a new position in Johnson & Johnson during the fourth quarter valued at $214,000. 66.02% of the stock is currently owned by institutional investors.
Shares of Johnson & Johnson (JNJ) opened at 132.15 on Tuesday. The company has a 50-day moving average price of $130.42 and a 200 day moving average price of $122.68. The firm has a market capitalization of $355.99 billion, a price-to-earnings ratio of 22.21 and a beta of 0.78. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.00.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $1.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.77 by $0.06. The firm had revenue of $17.77 billion during the quarter, compared to the consensus estimate of $18.02 billion. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. The business’s revenue was up 1.6% compared to the same quarter last year. During the same period last year, the company earned $1.68 earnings per share. Equities research analysts expect that Johnson & Johnson will post $7.10 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.54%. Johnson & Johnson’s dividend payout ratio is 56.47%.
TRADEMARK VIOLATION WARNING: “Huntington Steele LLC Has $483,000 Stake in Johnson & Johnson (NYSE:JNJ)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.com-unik.info/2017/07/18/huntington-steele-llc-has-483000-stake-in-johnson-johnson-nysejnj.html.
Several equities analysts have weighed in on JNJ shares. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 target price on the stock in a research note on Monday, April 24th. Cowen and Company reaffirmed a “buy” rating and set a $143.00 target price (up previously from $138.00) on shares of Johnson & Johnson in a research note on Friday, May 19th. UBS AG reaffirmed a “buy” rating and set a $136.00 target price on shares of Johnson & Johnson in a research note on Monday, May 15th. BMO Capital Markets reaffirmed a “buy” rating and set a $132.00 target price on shares of Johnson & Johnson in a research note on Friday, June 2nd. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $128.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 15th. Eleven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $133.65.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.